Global Plasma Fractionation Market 2024-2028
The plasma fractionation market is forecasted to grow by USD 10.00 bn during 2023-2028, accelerating at a CAGR of 6.09% during the forecast period. The report on the plasma fractionation market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of plasma products treated in respiratory diseases and AATD, a growing list of plasma-derived products, and an increase in M and A for producing plasma-based products.
Technavio's plasma fractionation market is segmented as below:
By Product
- Immunoglobulins
- Albumin
- Coagulation factor concentrates
- Protease inhibitors
- Others
By Application
- Immunology
- Neurology
- Hematology
- Critical care
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the growing elderly population and related disorders as one of the prime reasons driving the plasma fractionation market growth during the next few years. Also, government strategies for increasing self-sufficiency for plasma products and rising demand for plasma collection will lead to sizable demand in the market.
The report on the plasma fractionation market covers the following areas:
- Plasma fractionation market sizing
- Plasma fractionation market forecast
- Plasma fractionation market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading plasma fractionation market vendors that include ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., CSL Ltd., Emergent BioSolutions Inc., GC Biopharma corp. , Grifols SA, Hemarus Plasma, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A, LFB SA, Merck KGaA, Mitsubishi Chemical Group Corp., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions Netherlands BV, Sanquin, SK Inc., Takeda Pharmaceutical Co. Ltd., and Virchow Laboratories Ltd.. Also, the plasma fractionation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.